BackgroundRecent studies with intravenous (iv) application of ketamine show remarkable
but short-term success in patients with MDD. Studies in patients with chronic pain have used …

Objective: Narrative review of the literature on the efficacy and safety of subanaesthetic
doses of ketamine for the treatment of depression. Method: Medline and PubMed databases …

Ketamine is an anesthetic drug which is now used to treat chronic pain conditions and
psychiatric disorders, especially depression. It is an N-methyl-D-aspartate (NMDA) receptor …

Objective: Intravenous (IV) ketamine has rapid and robust antidepressant effects; however,
poor accessibility of the IV route often limits its use. Numerous alternative routes of …

Anecdotal reports suggest that the general anaesthetic drug ketamine, taken orally in low
doses, can give rise to some extra analgesia in patients with refractory neuropathic pain …

BackgroundKetamine has been demonstrated to improve depressive symptoms.
AimsEvaluation of efficacy, safety and feasibility of repeated oral ketamine for out-patients …

The analgesic effect of ketamine is primarily based on the antagonism of the N-methyl-d-
aspartate (NMDA) receptor. Activation of NMDA receptors may play a crucial role in the …

Ketamine is a parenteral anesthetic agent that provides analgesic activity at sub-anesthetic
doses. It is an N-methyl-D-aspartate (NMDA) receptor antagonist with opioid receptor …

Background: Ketamine research in depression has mostly used intravenous, weight-based
approaches, which are difficult to translate clinically. Intranasal (IN) ketamine is a promising …

The anaesthetic ketamine is used to treat various chronic pain syndromes, especially those
that have a neuropathic component. Low dose ketamine produces strong analgesia in …